Vanda Pharmaceuticals (VNDA) Gains from Sales and Divestitures (2010 - 2018)
Vanda Pharmaceuticals' (VNDA) quarterly Gains from Sales and Divestitures came in at $475367.0 in Q1 2018, up 36.79% year-on-year from $347504.0 in Q1 2017, and up 31.2% quarter-over-quarter from $362313.0 in Q4 2017.
Vanda Pharmaceuticals (VNDA) Gains from Sales and Divestitures (2010 - 2018) Analysis & Trends
Vanda Pharmaceuticals has disclosed Gains from Sales and Divestitures across 8 years of filings, most recently posting $475367.0 for Q1 2018.
- Gains from Sales and Divestitures for Q1 2018 came in at $475367.0, up 36.79% year-over-year; the trailing twelve-month figure through Mar 2018 was $475367.0 (up 36.79% YoY), and the FY2017 annual result was $362313.0, up 25.95% from the prior year.
- Gains from Sales and Divestitures came in at $475367.0 for Q1 2018 at Vanda Pharmaceuticals, up from $362313.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $475367.0 in Q1 2018 to a low of $209562.0 in Q1 2014.
- The 5-year median for Gains from Sales and Divestitures is $287666.0 (2016), against an average of $282623.5.
- Peak annual rise in Gains from Sales and Divestitures reached 37.48% in 2014, while the deepest fall reached 4.16% in 2014.
- Vanda Pharmaceuticals' Gains from Sales and Divestitures stood at $209562.0 in 2014, then increased by 10.27% to $231093.0 in 2015, then grew by 24.48% to $287666.0 in 2016, then grew by 25.95% to $362313.0 in 2017, then jumped by 31.2% to $475367.0 in 2018.
- The last three Gains from Sales and Divestitures figures came in at $475367.0 (Q1 2018), $362313.0 (Q4 2017), and $356127.0 (Q3 2017), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Vanda Pharmaceuticals | 345.46 Mn | 143.15 Mn | 48.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 475,367.00 |
| Mar 31, 2018 | 475,367.00 |
| Dec 31, 2017 | 362,313.00 |
| Dec 31, 2017 | 362,313.00 |
| Sep 30, 2017 | 356,127.00 |
| Sep 30, 2017 | 356,127.00 |
| Jun 30, 2017 | 350,004.00 |
| Jun 30, 2017 | 350,004.00 |
| Mar 31, 2017 | 347,504.00 |
| Mar 31, 2017 | 347,504.00 |
| Dec 31, 2016 | 287,666.00 |
| Dec 31, 2016 | 287,666.00 |
| Sep 30, 2016 | 287,666.00 |
| Sep 30, 2016 | 287,666.00 |
| Jun 30, 2016 | 287,666.00 |
| Jun 30, 2016 | 287,666.00 |
| Mar 31, 2016 | 287,666.00 |
| Mar 31, 2016 | 287,666.00 |
| Dec 31, 2015 | 231,093.00 |
| Dec 31, 2015 | 231,093.00 |